- Datum06.05.2024
- Uhrzeit14:00 - 15:00 Uhr
- Veranstalter
XTB
Jens Klatt
Moderator
Theravance Biopharma Inc.
Verkaufen
Kaufen
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Theravance Biopharma Inc. Kurse
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
1,18 %
Intraday
5,23 %
1 Woche
1,61 %
1 Monat
-15,84 %
Seit Jahresbeginn
-16,50 %
1 Jahr
-51,21 %
3 Jahre
-62,31 %
5 Jahre
Wikifolio
Passender Service zu Theravance Biopharma Inc.
Webinar zu Theravance Biopharma Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)8,210-11,980
- Jahrestief / Hoch ($)8,210-11,710
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Theravance Biopharma Inc.
Keine Dividenden verfügbar
Termine von Theravance Biopharma Inc.
- Mai13Theravance Biopharma Inc.Q1 2024 Earnings Release
- Jul31Theravance Biopharma Inc.Q2 2024 Earnings Release
- Nov5Theravance Biopharma Inc.Q3 2024 Earnings Release
Beschreibung
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
